Published in Medical Patent Week, December 6th, 2009
Earlier results of the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT), reported at a recent meeting of the American Society of Nephrology, showed that use of darbepoetin alfa to raise hemoglobin levels in patients with type 2 diabetes, chronic kidney disease (without dialysis) and moderate anemia (low red cell blood count) lessened the need for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.